Reviews CJC-1295

The sources / resolvable

CJC-1295 References and Citations

Every quantitative claim on this site maps to a numbered entry below. PMIDs and DOIs are provided so each source can be resolved directly.

Back to the reviewAbout this review

How to Read These Citations

Every inline [N] marker across this site resolves to the matching number below. The core CJC-1295 pharmacokinetic record rests on a small set of primary studies — Jette 2005, Teichman 2006 and Ionescu/Frohman 2006 — with the detection literature and the 2025 GHRH-analog review providing the analytical and contemporary context. Where a source is paywalled, the PMID or DOI still resolves to its abstract and metadata. The full citation list is reproduced below.

  1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. ↗
  3. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. ↗
  4. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. ↗
  5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. ↗
  6. Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. ↗
  7. An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormone analogs. J Pharm Biomed Anal. 2022. ↗
  8. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. 2021. ↗
  9. Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-MS. Anal Bioanal Chem. 2016. ↗
  10. Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea kinetics. Growth Horm IGF Res. 2009. ↗
  11. Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. ↗
  12. CJC-1295 development, pharmacokinetics, and regulatory status: ConjuChem Phase 2 program (NCT00267527, discontinued); 2024 FDA Pharmacy Compounding Advisory Committee review (reviewed, not recommended for the 503A bulks list); WADA Prohibited List Section S2; and the GH/IGF-1-axis safety literature (fluid retention, insulin sensitivity, IGF-1/cancer epidemiology). Composite of primary regulatory and clinical-trial records. ↗
  13. Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control. J Mass Spectrom. 2024. ↗
  14. Analysis of growth hormone releasing hormone and its analogs in urine using nano-LC-MS. J Pharm Biomed Anal. 2025. ↗